NasdaqCM:MDXGBiotechs
MiMedx Group (MDXG) Valuation: What Elevated Outlook and Strong Q3 Earnings Could Mean for Investors
MiMedx Group delivered upbeat third quarter earnings, with both revenue and net income rising sharply from last year. The company also boosted its outlook for sales growth in 2025, catching investors’ attention.
See our latest analysis for MiMedx Group.
MiMedx Group’s upbeat earnings and brighter full-year outlook have helped the stock regain some momentum, with a 13.6% gain in the past month after a rocky start to the year. While the latest share price sits at $7.44, the company’s three-year...